Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial

The VE of an RSVpreF vaccine vs no vaccine against respiratory and cardiovascular outcomes was similar among individuals ≥ 60 years of age with pre-existing ASCVD as compared with those without.

Authors

Institutions

Publication Details

Journal
European Heart Journal
Published
2025-08-18
DOI
https://doi.org/10.1093/eurheartj/ehaf679
Citations
3
Primary Topic
Respiratory viral infections research
Type
article
Field-Weighted Citation Impact
4.06

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial

Brian Lee Claggett, Lothar Wiese, Caroline Espersen, Camilla Ikast Ottosen et al.
3 citations
European Heart Journal
Respiratory viral infections research
4.06
article

Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial

Brian Lee Claggett, Lothar Wiese, Caroline Espersen, Camilla Ikast Ottosen, Mette Skovdal, Kristoffer Grundtvig Skaarup, Güldas Köse, Lars Køber, Mats Christian Højbjerg Lassen, Matias Greve Lindholm, Manan Pareek, Jens‐Ulrik Stæhr Jensen, Negar Aliabadi, Scott David Solomon, Filip Soeskov Davidovski, Lisa Steen Duus, Carsten Schade Larsen, Anne Bjerg Nielsen, Daniel Modin, Maria Dons, Bradford D. Gessner, Cyril Jean‐Marie Martel, Michael Dalager‐Pedersen, Elizabeth Begier, Niklas Dyrby Johansen, Tor Biering‐Sørensen, Sarah Louise Christensen, Claudia Schwarz, Julie Borchsenius, Ping Zhang, Anne Jensen, Lykke Larsen, Elisa Gonzalez, Katrine F Bernholm, Frederik H Fussing
article en
3 citations

Abstract

The VE of an RSVpreF vaccine vs no vaccine against respiratory and cardiovascular outcomes was similar among individuals ≥ 60 years of age with pre-existing ASCVD as compared with those without.

European Heart JournalVol. 46(41)
Statens Serum Institut (DK), University of Copenhagen (DK), Brigham and Women's Hospital (US), Steno Diabetes Centers (DK), Harvard University (US), Pfizer (United States) (US), European Council (BE), Aalborg University Hospital (DK), Odense University Hospital (DK), Aarhus University Hospital (DK), Copenhagen University Hospital (DK), Gentofte Hospital (DK), Rigshospitalet (DK), Zealand University Hospital (DK), Aalborg University (DK)
Pfizer
Openalex Percentile: Top 6%
Respiratory viral infections research
4.06
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.